[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-and-obese-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-and-obese-adults":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,70,91,123,147,177,209,240,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100616566","phase-1-a-study-of-synt-101-to-test-safety-tolerability-and-pharmacodynamics-of-synt-101-in-healthy-and-overweight-adults-100616566",false,"NCT07307274","A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults","A Phase 1 Randomised, Double-blind, Placebo-controlled Single Ascending and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYNT-101 in Healthy Adults and Healthy Adults Who Are Overweight or Have Obesity","Inclusion Criteria:\n\n* Must be able to understand the full nature and purpose of the study, including possible risks and adverse effects.\n* Adult males and females, 18 to 55 years of age (inclusive) at screening.\n* Medically healthy (in the opinion of the PI or delegate), as determined by pre-study medical history, and without clinically significant (CS) abnormalities.\n* Have suitable venous access for blood sampling.\n* Willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.\n\nExclusion Criteria:\n\n* Known hypersensitivity to the study drug or any of the study drug ingredients.\n* History of anaphylaxis or other significant allergy which, in the opinion of the PI (or delegate), would interfere with the volunteer's ability to participate in the study.\n* History or presence of CS cardiovascular, pulmonary, hepatic, renal, haematological, endocrine, immunologic, dermatologic, psychiatric, or neurological disease\u002Fdisorder, including any acute illness, within the past 3 months determined by the PI (or delegate) to be clinically relevant.",true,"ALL","18 Years","55 Years",{"count":21,"type":22},64,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.",[28,29],"Healthy","Overweight and Obese Adults","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-04-29","ACTUAL",{"date":36,"type":34},"2026-01-13",{"date":38,"type":22},"2026-12-31",{"name":40,"class":41},"Syntis Bio","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100636154","a-12-week-field-trial-of-the-movmonos-physical-activity-support-program-100636154","NCT07561996","A 12-week Field Trial of the Movámonos Physical Activity Support Program","Movámonos: Translation and Cultural Adaptation of a Theory-Based Physical Activity Support Program for Spanish-Speaking Adults - Aim 2","Movámonos","Inclusion Criteria:\n\n* Men and Women\n* Age 18-65 years\n* Speak Spanish as their primary language\n* Self-identify as Hispanic or Latino\n* Body Mass Index 25-45 kg\u002Fm2\n* Insufficiently active (defined as \\\u003C150 min\u002Fweek of voluntary exercise at moderate intensity over the past 3 months)\n* Willing not to enroll in any other formal weight loss, physical activity program, or fitness center membership over the next 6 months.\n* Capable and willing to give informed consent, understand exclusion criteria, attend the Movámonos program sessions, and complete outcome measures.\n* Able to provide signed physician clearance for exercise if indicated by the Physical Activity Readiness Questionnaire (PAR-Q+) and determined by the study PI.\n\nExclusion Criteria:\n\n* Considered high risk, based on the American College of Sports Medicine Guidelines for Exercise Testing and Prescription33 (i.e. have cardiovascular disease symptoms or known cardiovascular disease, diabetes, or end-stage renal disease). These conditions are identified in the PAR-Q+.\n* Females who are currently pregnant or lactating, were pregnant within the past 3 months, or planning to become pregnant in the next 6 months will also be excluded\n* Self-reported cardiovascular disease:\n* Cardiac, peripheral vascular, or cerebrovascular disease\n* Self-reported symptoms suggestive of cardiovascular disease: pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from cardiac ischemia; shortness of breath at rest or with mild exertion; dizziness or syncope; orthopnea or paroxysmal nocturnal dyspnea; ankle edema; palpitations or tachycardia; intermittent claudication.\n* Self-reported end-stage renal disease\n* Self-reported diabetes (history of type 1 or type 2 diabetes; fasting glucose ≥126 mg\u002FdL or Hemoglobin A1C ≥6.5%)\n* Uncontrolled hypertension, defined as diastolic blood pressure \\>100 mmHG, systolic blood pressure \\>160 mmHG, or resting heart rate \\>100 bpm as measured in duplicate at the screening visit after 5 minutes of rest in a seated position.\n* Self-reported pulmonary disease requiring chronic oxygen supplementation; severe asthma or chronic obstructive pulmonary disease requiring hospitalization in past year.\n* Plans to relocate in the next 6 months\n* Currently participating in or planning to participate in any formal weight loss, dietary modification, or physical activity\u002Fexercise programs or clinical trials.\n* Current severe depression or history of severe depression within the previous year, based on DSM-IV-TR criteria for Major Depressive Episode. Scores \\>=16 on CES-D will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.\n* History of other significant psychiatric illness (e.g., psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study PI would interfere with ability to adhere to the exercise intervention.\n* History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Scores \\>20 on the EATS-26 Spanish version34 or global scores ≥2.3 on the Spanish version of the Eating Disorder Examination Questionnaire (S-EDE-Q)35,36 suggestive of a possible eating disorder will require further assessment by the Study PI to determine if it is appropriate for the subject to participate in the study.\n* Current alcohol or substance abuse\n* Nicotine use (current or past 6 months)\n* Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g., appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants)\n* Regular use of obesity pharmacotherapeutic agents within the last 6 months.\n* Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and\u002For abdominoplasty if performed \\> 1 year before screening, (2) lap banding if the band has been removed \\> 1 year before screening, (3) intragastric balloon if the balloon has been removed \\> 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed \\> 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed \\> 1 year before screening.\n* Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.\n* Hematocrit, white blood cell count or platelets significantly outside the normal reference range.\n* Triglycerides \\> 400 mg\u002FdL\n* LDL cholesterol \\>200 mg\u002FdL","65 Years",{"count":53,"type":22},20,[55],"NA","The objective of this study is to design and refine an activity support program, called Movámonos, for adults with overweight or obesity who speak Spanish. The primary outcomes are feasibility and acceptability of the Movámonos physical activity support program.",[29,58],"Physical Inactivity","NOT_YET_RECRUITING","2026-04-24",{"date":62,"type":34},"2026-05-01",{"date":64,"type":22},"2026-05-15",{"date":66,"type":22},"2027-07-31",{"name":68,"class":69},"University of Colorado, Denver","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100616117","phase-4-rws-of-of-liraglutide-alone-and-in-combination-with-orlistat-for-weight-loss-in-overweightobese-patients-100616117","NCT07301437","RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight\u002FObese Patients.","Inclusion Criteria:\n\n* BMI: ≤ 35 kg\u002Fm² and ≥ 30 kg\u002Fm², or ≥ 27 kg\u002Fm² and having at least one obesity-related complication (such as hypertension, type 2 diabetes, dyslipidemia)\n* Voluntarily sign the informed consent form, agreeing to cooperate in completing the 24-week treatment and follow-up.\n* No severe cognitive impairment or mental illness, and able to understand and comply with the research requirements.\n\nExclusion Criteria:\n\n* Allergy to liraglutide, orlistat or excipients\n* Severe liver and kidney dysfunction: ALT or AST\\> three times the upper limit of normal, or eGFR \\\u003C30 mL\u002Fmin\n* Thyroid diseases: Personal or family history of medullary thyroid cancer, or uncontrolled hyperthyroidism\u002Fhypothyroidism\n* Gastrointestinal diseases: Having gastrointestinal surgery within 3 months, or inflammatory bowel disease or active gastric and duodenal ulcers\n* Pregnant or lactating women\n* Others: Type 1 diabetes, malignant tumors, severe cardiovascular diseases (such as NYHA IV).",{"count":78,"type":22},120,[80],"PHASE4","To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight\u002Fobese patients.",[29],"2026-03-20",{"date":85,"type":34},"2026-03-23",{"date":62,"type":22},{"date":88,"type":22},"2027-08-31",{"name":90,"class":69},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":42},"100562188","phase-2-study-of-the-efficacy-and-safety-of-nicotinamide-in-patients-with-liver-fibrosis-nicofib-100562188","NCT06599918","Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)","Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Nicotinamide in Patients With and Liver Fibrosis (NICOFIB)","NICOFIB","Inclusion Criteria:\n\n* Patients aged between 18 and 85 years.\n* Diagnosis of non-alcoholic fatty liver disease (NAFLD) by their referring physicians (NAFLD defined as the presence of hepatic steatosis and in the absence of significant alcohol consumption, having excluded other liver diseases).\n* BMI between 27-40 kg\u002Fm2.\n* Fibroscan® value greater than 9.2 kPa, obtained within the last 6 months prior to the start of the study.\n\nExclusion Criteria:\n\n* Patients with any medical condition or illness that, in the opinion of the investigator, could interfere with the study results and\u002For affect the patients' ability to participate or complete the study.\n* History of clinically significant heart disease (ejection fraction \\\u003C40% \\[normal range 50-70%\\], heart failure defined as New York Heart Association \\[NYHA\\] Class \\> 2; clinically significant congenital or acquired valvular disease; symptomatic coronary artery disease such as myocardial infarction or angina, history of unstable arrhythmias, history of atrial fibrillation).\n* Decreased renal function (estimated glomerular filtration rate \\\u003C45 mL\u002Fmin\u002F1.73 m2, calculated using the CKD-EPI formula) at screening.\n* Alcohol consumption exceeding 30 g\u002Fday in men or 20 g\u002Fday in women.\n* Patients with significant impairment of liver function in the selection analysis defined as repeated values of AST, ALT, and bilirubin \\> 3 times the upper limit of normal.\n* Positive for hepatitis B surface antigen or hepatitis C antibodies.\n* Patients with hepatocellular carcinoma.\n* Patients with liver cirrhosis (Fibroscan® \\> 18, compatible biopsy, or those who have experienced decompensations of cirrhosis).\n* Patients diagnosed with human immunodeficiency virus (HIV).\n* Patients with hypersensitivity or a history of severe allergies to NAM or excipients used in the preparation of capsules (NAM and placebo).\n* Patients with iodinated contrast allergy.\n* History or evidence of an autoimmune disorder considered clinically significant by the investigator or requiring systemic, chronic use of systemic corticosteroids or other immunosuppressants.\n* Patients on treatment with hepatotoxic drugs (amiodarone, immunosuppressants, ART, antituberculosis drugs, corticosteroids, etc.).\n* Patients consuming narcotic and psychotropic substances with hepatotoxic effects.\n* Individuals with incapacitating diseases or cognitive impairment.\n* Institutionalized patients or those without a fixed address.\n* Principal investigator's discretion in case of indications of low adherence to the trial or follow-up visits.\n* Individuals with a life expectancy of less than 12 months.\n* Patients participating in another interventional clinical trial, excluding observational\u002Fnatural history studies, at the start of the study or within the last 30 days before the start of the study.\n* Previous use of vitamin B3 (NAM), with abstinence required for at least 3 months before screening.\n* Pregnant women as determined by a positive high-sensitivity serum or urine pregnancy test (minimum sensitivity of 25 IU\u002FL or equivalent units of hCG) within 24 hours prior to screening, dosing, or completion of the study. Women of childbearing potential (WOCBP) will undergo a pregnancy test (serum or urine) 24 hours prior to screening, dosing, or completion of the study. Such participants must use a highly effective contraceptive method, such as combined hormonal contraceptives or intrauterine device (IUD), in accordance with the Clinical Trial Facilitation Group, throughout the entire study.\n* Breastfeeding women.\n* Patients undergoing treatment\u002Fsupplementation with vitamin E.\n* Patients receiving probiotics.\n* Patients on the waiting list for bariatric surgery in the next 12 months.\n* Patients undergoing treatment with drugs that may have an effect on the progression of liver disease.\n* Drugs for the treatment of T2DM with effects on NAFLD (GLP-1 analogs, thiazolidinediones such as pioglitazone) initiated within 6 months before the study start.\n* Drugs for the treatment of T2DM with effects on intestinal microbiota (metformin, α-GI inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors) initiated within 6 months before the study start.\n* Patients who do not sign the informed consent.\n* Patients with contraindications to the contrast agent to be used in imaging tests.","85 Years",{"count":101,"type":22},30,[103],"PHASE2","The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.\n\nThe main question it aims to answer is:\n\n\\- To determine if the treatment with NAM is able to arrest, or even reduce, the hepatic fibrosis.\n\nIn addition, we also want to study the effect of NAM on:\n\n* General parameters (weight, HOMA-IR, etc).\n* Adiposity distribution (liver and body).\n* Systemic inflammation.\n* Thermogenic capacity of adipose tissue.\n* Microbiota composition.\n\nResearchers will compare NAM to a placebo, to see if NAM can arrest or revert hepatic fibrosis and its associated effects.\n\nParticipants will take either NAM or placebo. The dosage will be 1.2g\u002Fm2 NAM per day, for one year.",[106,107,108,109,110,29],"Fatty Liver","Obesity","Hepatic Fibrosis","NAFLD","Nicotinamide",[110,112,113],"Fatty liver","Nafld","2025-11-14",{"date":116,"type":34},"2025-11-18",{"date":118,"type":34},"2024-04-23",{"date":120,"type":22},"2028-12",{"name":122,"class":69},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":23,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":42},"100607028","eatits-obesity-intervention-effects-on-weight-eating-habits-and-health-100607028","NCT07183228","Eatit's Obesity Intervention: Effects on Weight, Eating Habits and Health","Eatit's Multimodal Digital Lifestyle Intervention for Obesity: A Clinical Pilot Study on Effects on Weight, Self-Rated Eating Habits and Self-Rated Health","Inclusion Criteria:\n\n* Age 18 years or older\n* Body mass index (BMI) ≥ 30\n* BMI 27-30 in combination with at least one of the following:\n\n  1. Has received a diagnosis of obesity from another healthcare provider.\n  2. Has a comorbidity (according to the defined diagnosis list under the heading Comorbidities below).\n  3. Has central obesity, defined as waist circumference \\> 80 cm for women or \\> 94 cm for men.\n  4. Kostindex score of 4 or lower - eligible for treatment due to increased risk of rapid future weight gain. Dietitian-led intervention may significantly impact weight development in this group.\n* Ability to read and understand Swedish\n* Does not currently use, and does not plan to initiate the use of, appetite-suppressing medication\n* Not pregnant\n* Patients with BMI \\> 40, As long as there is no contraindication for treatment, treatment is offered. A dietitian may deny the patient the Eatit program if the dietitian assesses that the need for care is too great, and that Eatit's treatment cannot meet the patient's needs.\n\nComorbidities:\n\n* Cardiovascular disease This is a large group of diagnoses, e.g. previous myocardial infarction or stroke, angina pectoris, heart failure, etc.\n* Hypertension\n* Elevated blood pressure, above 130\u002F85 mmHg or ongoing treatment for previously diagnosed hypertension\n* Hyperlipidemia\n* Triglyceride levels ≥ 1.7 mmol\u002FL or on treatment for elevated triglycerides, or LDL \\> 3.0 mmol\u002FL at low risk, or on treatment for high cholesterol, or reduced HDL-C \\\u003C40 mg\u002FdL for men, \\\u003C50 mg\u002FdL for women, or on treatment for HDL-C\n* Obstructive sleep apnea\n* Type 1 diabetes\n* Type 2 diabetes\n* Prediabetes (fasting glucose ≥ 6.1 or HbA1c \\> 42 without a diabetes diagnosis)\n* Fatty liver\n* Polycystic ovary syndrome, PCOS\n* Osteoarthritis in the lower body (e.g. hip, knee, or foot)\n\nExclusion Criteria:\n\n* BMI: Patients with BMI \\\u003C 27 are excluded from treatment.\n* Medical conditions: Patients with conditions where weight loss or weight gain may worsen the disease are excluded. For example: cancer or chronic obstructive pulmonary disease, COPD.\n* Multimorbidity: Individuals with extensive comorbidities may have complex healthcare needs requiring more comprehensive medical support than Eatit can provide.\n* Untreated depression may hinder participation in the program and should be managed with medical or psychological support.\n* Untreated or ongoing eating disorder (bulimia nervosa, binge eating disorder, anorexia, atypical anorexia, ARFID) should be treated in a specialized eating disorder unit.\n* Severe psychiatric illness (such as psychosis or schizophrenia) without ongoing support.\n* Ongoing substance abuse (alcohol, narcotics, or medication) is a contraindication for participation and requires specialized addiction care.\n* Suicidal behavior or self-harm in the past six months. Acute mental illness requires immediate and specialized interventions.\n* Requires individual assessment. Certain conditions require individual evaluation as they may negatively affect treatment outcomes. This means that the treating dietitians should ask follow-up questions to ensure that participation in the program is feasible.\n* Symptoms of binge eating not meeting criteria for binge eating disorder: Ensure that the person is willing to work with the program, not skip meals, and will inform you if the binge eating worsens.\n* Depression under psychiatric care: Ask follow-up questions about what support the person is receiving and his or her current mental state.\n* Bipolar disorder: Ask follow-up questions about what support the person is receiving and his or her current mental state.\n* Exhaustion syndrome\u002Fstress: Ask follow-up questions to determine whether treatment is feasible at this time or if the patient needs to manage the stress in other ways first.\n* Neuropsychiatric disorders: To benefit from the program, sufficient concentration ability and capacity for structure\u002Fplanning in daily life are required. In case of a neuropsychiatric diagnosis, follow-up questions should be asked about whether the person believes that he or she can manage texts and tasks that take approximately 2-3 hours per week.\n* High degree of psychiatric comorbidity has in some studies been shown to be a complicating factor, and this should also be considered at the start of treatment. Ask follow-up questions about what support the person is receiving and his or her current mental state.\n* Severe sleep problems: Sleep deprivation may lead to increased appetite and reduced cognitive capacity, making it difficult to engage with treatment. Ask follow-up questions about possible undiagnosed sleep apnea or potential need for other care to address the sleep problems.",{"count":131,"type":22},93,[55],"Obesity is a growing public health problem in Sweden, but access to care varies depending on geographical location. Eatit´s multimodal digitally dietitian-supported lifestyle intervention offers an accessible treatment alternative, but its clinical effects in practice need to be documented.\n\nThe aim of this pilot study is to evaluate the effect of Eatit´s multimodal digitally dietitian-supported lifestyle intervention for weight loss in adults with obesity.\n\nThe main question is:\n\n\\- Does body weight change after six months of using the program?\n\nSecondary questions are:\n\n* Does waist size change after six months of using the program?\n* Do self-rated eating habits improve after six months of using the program?\n* Does self-rated health improve after six months of using the program?\n\nParticipants will use the Eatit program for six months and answer questions about their weight, waist size, eating habits and health. The program integrates behavior change techniques with individualized nutrition counseling provided by licensed dietitians.\n\n* During the first three months, participants use Eatit's core program through the app, with weekly support by a dietitian via video calls and text messages.\n* The core program consists of a weekly reading section combined with a related homework assignment.\n* After completing the core program, participants continue with monthly video sessions with a dietitian, focusing on the skills that were most helpful during the initial phase or on areas such as receiving support to initiate physical activity.\n* Weight and waist size are recorded in the app every week.\n* Questionnaires on eating habits and health are completed at baseline, after three months, and after six months.",[29,135],"Obese Patients (BMI ≥ 30 kg\u002Fm²)",[107,137],"Weight Reduction Programs","2025-09-18",{"date":140,"type":34},"2025-09-19",{"date":142,"type":34},"2025-09-03",{"date":144,"type":22},"2026-08-01",{"name":146,"class":41},"Eatit AB",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":23,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100600288","plant-based-online-weight-loss-through-education-and-resources-program-and-study-100600288","NCT07095543","Plant-Based Online Weight Loss Through Education and Resources Program and Study","Feasibility, Implementation, and Efficacy of a Plant-based Online Weight Loss Through Education and Resources Program and Study (POWER Study)","POWER","Inclusion Criteria:\n\n* U.S. men and women meeting the age of majority, defined as follows:\n\nAge 19 or older in Nebraska and Alabama. Age 21 or older in Puerto Rico. Age 18 or older in all other states.\n\n* Able and willing to travel to Washington DC for a dual-energy х-rау absorptiometry (DXA) scans before and after the program.\n* Able and willing to complete laboratory assessments at a local LabCorp facility before and after the program.\n* Able and willing to participate in all components of the study.\n* BMI of 25 or more (23 or more in persons of Asian origin).\n* Access to the internet.\n* English fluency.\n\nExclusion Criteria:\n\n* Use of recreational drugs in the past 6 months.\n* Pregnancy or intention to become pregnant during the study period, as verified by self-report.\n* Unstable medical or psychiatric illness.\n* Inability to maintain medication regimen as prescribed by personal healthcare provider.\n* Current or expected use of any weight loss medication during the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor\u002Fglucose-dependent insulinotropic polypeptide (GIP) agonists.\n* Use of any weight loss medication within the 12 months preceding the study period, including but not limited to, glucagon-like peptide-1 (GLP-1) receptor agonists and combination GLP-1 receptor\u002Fglucose-dependent insulinotropic polypeptide (GIP) agonists.\n* Body weight greater than 182 kg.\n* Current diagnosis of eating disorder.\n* Intention to follow another weight loss method during the study period.",{"count":156,"type":22},100,[55],"This is an interventional study that will evaluate the feasibility, implementation, and efficacy of an online, 12-week, plant-based, nutrition education program in a community setting. Participants will meet with a physician and a registered dietitian once a week to learn about a plant-based diet and receive support and practical help in making the dietary changes. Body composition, blood sugar control, cholesterol levels, and food costs will be measured at the start and end of the study.",[160,29],"Type 2 Diabetes",[162,163,164,165,166,107,167],"Plant-based diet","Vegan diet","type 2 diabetes","Weight loss","Overweight","Cholesterol","2025-07-30",{"date":170,"type":34},"2025-08-03",{"date":172,"type":22},"2025-10-01",{"date":174,"type":22},"2028-10-30",{"name":176,"class":69},"Physicians Committee for Responsible Medicine",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":42},"100597988","sex-hormones-as-regulators-of-the-age--and-sex-dependent-benefits-of-caloric-restriction-100597988","NCT07065643","Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction","GendAge Weight Loss Study: Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction","GendAge","Inclusion criteria\n\n* Adults (aged over 18years) who are healthy but overweight\u002Fobese (BMI 27-45kg\u002Fm2) males and females as:\n* 15 women (age 40 or less years)\n* 15 men (age 40 or less years)\n* 15 women (age 55-65 years) in menopause\\*; not taking Hormone Replacement Therapy (HRT)\n* 15 men (age 55-65 years)\n* 15 women (age 55-65 years) in menopause; taking HRT\\*\\*\n\n  * menopause definition is no menstrual period for 12 months \\*\\*HRT inclusion criteria - women will have continuously taken oestrogen HRT for 24 months\n\nExclusion criteria:\n\nPotential volunteers will be asked to fill in a health questionnaire at the screening visit to assess their suitability for the study. This information will allow us to exclude participants.\n\nMedication exclusion criteria, current use :-\n\n• weight loss medication (e.g. GLP agonists), β-blockers, antihistamines, antipsychotics, benzodiazepines, barbiturates, melatonin, Ritalin, modafinil, soporifics, hypnotics, antiepileptic drugs, diabetes medication (e.g. metformin or insulin).\n\nSelf-reported medical exclusion criteria:\n\n* Females who are planning to be pregnant, are pregnant or are breastfeeding\n* Anyone with coeliac disease or gluten intolerance or food allergy\n* Anyone with diagnosed T1 or T2 diabetes\n* Anyone suffering from a psychiatric disorder or any type of substance abuse\n\nOther exclusion criteria\n\n* Anyone following a vegetarian or vegan diet\n* Anyone currently following a weight loss programme (that may be affecting lifestyle, physical activity \\& diet) or undergone gastric band\u002Freduction surgery; including GLP agonist (e.g. Semaglutide injection, Ozempic®).\n* Anyone currently participating in another research study\n* Anyone with unsuitable veins for blood sampling\n* Anyone who is unable to fluently speak, read and understand English\n* Anyone who is unable to comply to an alcohol-free diet for 6 weeks\n* Anyone unable to give fully informed consent",{"count":186,"type":22},75,[55],"Obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, primarily due to elevated abdominal fat storage. With nearly two-thirds of the UK population living with overweight or obesity, there is an urgent necessity for evidence-based public health guidance to promote healthy weight. Calorie deficit can facilitate weight loss and body fat reduction, leading to health benefits, such as improved blood glucose control. Current weight management advice centres on lifestyle modification, incorporating changes to diet and physical activity to support a calorie deficit. However, existing dieting recommendations fail to consider gender or age. This is a surprising oversight, as it is well established that health outcomes vary significantly between men and women across the lifespan. Further, the menopause may have an impact on fat storage linked to changes in sex hormones. Our recent research, involving both mice and humans, has indicated that females are less responsive to weight loss and fat reduction during dieting. This study aims to understand endocrine and metabolic sex-based differences in obesity and calorie restriction, with a particular focus on women's health. We plan to conduct a diet study with 75 participants, encompassing both younger and older men and women, to monitor changes in energy expenditure and body composition using gold-standard techniques, such as doubly-labelled water. Blood and abdominal fat tissue samples will be collected to investigate how sex hormones might elucidate these differences. The aim of the study is to enhance our understanding of diet and women's health to combat obesity and promote healthy ageing.",[29,28],[191,192,193,194,195,196,197,198,199],"caloric restriction","low calorie diet","menopause","overweight","obesity","weigh loss","ageing","energy expenditure","body composition","2025-07-17",{"date":202,"type":34},"2025-07-18",{"date":204,"type":34},"2025-07-09",{"date":206,"type":22},"2027-12",{"name":208,"class":69},"University of Aberdeen",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":16,"sex":217,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":42},"100582865","acute-effects-of-isoenergetic-hiie-vs-mice-on-key-parameters-of-fat-mass-loss-in-young-females-with-overweight-or-obesity-100582865","NCT06868862","Acute Effects of Isoenergetic HIIE Vs. MICE on Key Parameters of Fat Mass Loss in Young Females with Overweight or Obesity","Acute Physiological Responses to Isoenergetic High-Intensity Interval Vs. Moderate-Intensity Continuous Exercise in Overweight or Obese Young Females: Focus on Catecholamines, Oxygen Consumption, Lipid Utilization, and Appetite Regulation","COMEFIT","Inclusion Criteria:\n\n* women with overwieght or obesity (BMI: 25-35 kg\u002Fm²)\n\nExclusion Criteria:\n\n* contraceptive use\n* menopause\n* irregular menstrual cycle\n* medical contraindications to intense physical activity,\n* painful joints,\n* taking ß-blocker","FEMALE","20 Years","45 Years",{"count":221,"type":22},15,[55],"Overweight and obesity, particularly increased total and\u002For abdominal fat mass (FM), are strongly linked to the development of cardiovascular diseases. Managing obesity effectively requires lifestyle and dietary modifications, including increased physical activity. Among the various exercise strategies, Moderate-Intensity Continuous Training (MICT) and High-Intensity Interval Training (HIIT) are widely recommended for reducing FM. Compared to MICT, HIIT is a time-efficient approach, often perceived as more enjoyable, and has been shown to promote greater total and abdominal fat loss in a shorter period. However, the precise mechanisms underlying this enhanced fat loss remain unclear.\n\nThis study aims to compare the acute effects of two isoenergetic exercise sessions - MICE (Moderate-Intensity Continuous Exercise) and HIIE (High-Intensity Interval Exercise) - on key physiological responses involved in fat mass loss. Specifically, we will assess plasma catecholamine levels during exercise and recovery, as well as oxygen consumption, substrate oxidation, and appetite over the 2-hour post-exercise period in young females with overweight or obesity. By elucidating the role of catecholaminergic stimulation as a potential regulator of fat mass loss, this research could provide valuable insights for optimizing exercise strategies in weight management and metabolic health.",[29,225],"High Intensity Interval Exercise (HIIE)",[227,228,229,230,195],"oxygen consumption","high intensity interval training","substrate oxydation","catecholamines","2025-03-04",{"date":233,"type":34},"2025-03-11",{"date":235,"type":34},"2025-02-01",{"date":237,"type":22},"2025-12-30",{"name":239,"class":69},"Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100574305","effect-of-vegetables-on-weight-status-of-university-population-100574305","NCT06757556","Effect of Vegetables on Weight Status of University Population","Effect of Consumption of Non-starchy Vegetables on Weight Status of Overweight and Obese University Population","Inclusion Criteria:\n\n* Overweight and obese individuals with BMI 23kg\u002Fm\\^2\n* Population of UVAS (students, teaching and non-teaching staff)\n\nExclusion criteria:\n\n* Normal weight and underweight individuals with BMI \\\u003C23kg\u002Fm\\^2\n* Non-UVAS (University of Veterinary and Animal Sciences) population.",{"count":248,"type":22},40,[55],"Obesity rates have more than doubled globally since 1990, with 2.5 billion overweight adults by 2022, and 890 million of them living with obesity (WHO, 2023). In Pakistan, approximately 30% of adults are overweight or obese, with 21% overweight and 9% obese. Non-communicable diseases now account for 58% of deaths in the country. WHO recommends daily consumption of non-starchy vegetables to aid weight loss and reduce BMI and fat mass, especially for overweight and obese individuals. This randomized controlled trial (RCT) will be conducted at the University of Veterinary and Animal Sciences (UVAS) in Lahore, Pakistan, targeting the university population, including students, teaching, and non-teaching staff with BMI ≥23 kg\u002Fm². A total of 40 participants will be recruited, with 20 assigned to the intervention group (receiving 2-3 cups of non-starchy vegetables daily) and 20 to the control group (receiving only dietary guidelines). Weight, BMI, and fat mass will be measured before and after the trial using an InBody 270. The data will be analyzed using SPSS version 25, with paired and independent t-tests to compare changes within and between groups. Multiple logistic regression will examine the relationship between vegetable consumption and changes in weight, BMI, and fat mass. This study aims to assess the impact of daily non-starchy vegetable intake on the weight, BMI, and fat mass of the overweight and obese university population.",[252,29],"Obesity Control","2025-01-03",{"date":255,"type":34},"2025-01-07",{"date":257,"type":22},"2025-02-17",{"date":259,"type":22},"2025-09-08",{"name":261,"class":69},"University of Veterinary and Animal Sciences, Lahore - Pakistan",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":272,"phases":4,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100564221","screening-for-malnutrition-in-obese-patients-100564221","NCT06626360","Screening for Malnutrition in Obese Patients","SCreening fOr Malnutrition and Obesity in Patients With COVID-19 and Other Diseases","SCOOP","Inclusion Criteria:\n\n* Age 18 years or older\n* Overweight (BMI of 25 kg\u002Fm² or higher)\n\nExclusion Criteria:\n\n* Physically or mentally unable to participate.\n* Severe cognitive disorder or severe emotional instability, as assessed by the attending nurse or physician.\n* Insufficient proficiency in the Dutch language to express themselves properly and no interpreter or assistant to help.\n* Patient resides in a nursing or care home.",{"count":271,"type":22},2000,"OBSERVATIONAL","More than half of the Dutch population is overweight or obese, which is associated with an increased risk of COVID-19 and worse outcomes during a COVID-19 infection. In addition, malnutrition and loss of muscle mass are often reported with COVID-19, as well as with cancer and other diseases. Malnutrition and overweight or obesity can coexist, even within the same individual. It is still unclear which mechanisms contribute to the worse outcomes of COVID-19 and other diseases in case of overweight, malnutrition, and a combination of both. The aim of this study is to identify which parameters are associated with worse disease outcomes through literature research and database research (COVID-19 and cancer, more than 150.000 participants). In addition, a clinical study will be conducted aiming to develop a simple screening tool for the recognition of the coexistence of malnutrition and overweight or obesity in clinical practice.",[29,275],"Malnutrition or Risk of Malnutrition",[166,107,277],"Malnutrition","2024-11-07",{"date":280,"type":34},"2024-11-08",{"date":282,"type":34},"2024-10-02",{"date":284,"type":22},"2025-08-31",{"name":286,"class":69},"HAN University of Applied Sciences",3]